Emerging new technology: QSAR analysis and mo calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, abcg2 (BCRP)

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 1, 2010, Pages 72-83

  Saito, Hikaru ^a,b   An, Ran ^a   Hirano, Hiroyuki ^a   Ishikawa, Toshihisa ^a,c  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

ABC transporter; ABCG2 (BCRP); Cancer; Protein kinase inhibitor; Quantitative structure activity relationship (QSAR)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BOHEMINE; BREAST CANCER RESISTANCE PROTEIN; GEFITINIB; HEMATOPORPHYRIN; IMATINIB; IRINOTECAN; MERCAPTOETHANOL; METHOTREXATE; NOVOBIOCIN; OLOMOUCINE; PHEOPHORBIDE; PRAZOSIN; PROTEIN KINASE INHIBITOR; PURVALANOL A; QUERCETIN; ROSCOVITINE; TACROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; WHI P 180;

BINDING SITE; CELL CYCLE PROGRESSION; CELL MEMBRANE; CELL SURVIVAL; DEPIGMENTATION; DISULFIDE BOND; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG INHIBITION; DRUG INTERACTION; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GLYCOSYLATION; HUMAN; HYDROLYSIS; HYDROPHOBICITY; HYPOPIGMENTATION; MOLECULAR MODEL; MOLECULAR WEIGHT; NONHUMAN; PHOTOSENSITIVITY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PROCESSING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 77949280630     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.72     Document Type: Review

References (49)

1. Higgins, C. F.: ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol., 8: 167-113 (1992)
2. Klein, I., Sarkadi, B. and Varadi, A.: An inventory of the human ABC proteins. Biochim. Biophys. Acta, 1461: 237-262 (1999).
3. Dean, M., Rzhetsky, A. and Allikmets, R.: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res., 11: 1156-1166 (2001).
4. Ishikawa, T.: Multidrug resistance: genomics of ABC transporters. In Cooper, D. N. (ed.): Nature Encyclopedia of the Human Genome, London, Nature Publishing Group, 2003 vol. 4: pp. 154-160.
5. Borst, P. and Oude Elferink, R.: Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 71: 537-592 (2002).
6. Ambudkar, S. V., Dey, S. Hrycyna, C. A., Ramachandra, M., Pastan, I. and Gottesman, M. M.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39: 361-398 (1999).
7. Ling, V.: Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 40: S3-S8 (1997).
8. Holland, I. B., Benabdelhak, H., Young, J., Pimenta, A., Schmitt, L. and Bright, M. A.: Bacterial ABC Transporters Involved in Protein Translocation. In Holland, I. B., Cole, S. P. C., Kuchler, K. and Higgins, C. F. (ed.): ABC Proteins: from bacteria to man, London, Academic Press (Elsevier), pp. 209-242 (2003).
9. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K. and Ross, D. D.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670 (1998).
10. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. and Dean, M.: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339 (1998).
11. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T. and Bates, S. E.: Molecular cloning of cDNAs which are highly overexpressed in mitoxantron-resistant cells: demonstration of homology to ABC transporter genes. Cancer Res., 59: 8-13 (1999).
12. Vlaming, M. L., Lagas, J. S. and Schinkel, A. H.: Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev., 61: 14-25 (2009).
13. Wakabayashi, K., Nakagawa, H., Tamura, A., Koshiba, S., Hoshijima, K., Komada, M. and Ishikawa, T.: Intramolecular disulfide bond is a critical checkpoint determining degradative fates of ABC transporter ABCG2 protein. J. Biol. Chem., 282: 27841-27846 (2007).
14. Wakabayashi, K., Tamura, A., Saito, H., Onishi, Y. and Ishikawa, T.: Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev., 38: 371-391 (2006).
15. Wakabayashi-Nakao, K., Tamura, A., Furukawa, T., Nakagawa, H. and Ishikawa, T.: Quality control of human ABCG2 protein in the endoplasmeic reticulm: ubiquitination and proteasomal degradation. Adv. Drug. Deliv. Rev., 61: 66-72 (2009).
16. Nakagawa, H., Wakabayashi-Nakao, K., Tamura, A., Toyoda, Y., Koshiba, S. and Ishikawa, T.: Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of human ATP-binding cassette transporter ABCG2. FEBS J., 276: 7237-7252 (2009).
17. Tamura, A., Wakabayashi, K., Onishi, Y., Takeda, M., Ikegami, Y., Sawada, S., Tsuji, M., Matsuda, Y. and Ishikawa, T.: Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci., 98: 231-239 (2007).
18. Nakagawa, H., Tamura, A., Wakabayashi, K., Hoshijima, K., Komada, M., Yoshida, T., Kometani, S., Matsubara, T., Mikuriya, K. and Ishikawa, T.: Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem. J., 411: 623-631 (2008).
19. Furukawa, T., Wakabayashi, K., Tamura, A., Nakagawa, H., Morishima, Y., Osawa, Y. and Ishikawa, T.: Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteosomal degradations. Pharm. Res., 26: 469-479 (2009).
20. Vlaming, M. L., Lagas, J. S. and Schinkel, A. H.: Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev., 61: 14-25 (2009).
21. Allen, J. D. and Schinkel, A. H.: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Therapeutics, 1: 427-434 (2001).
22. Stewart, C. F., Leggas, M., Scheutz, J. D., Panetta, J. C., Cheshire, P. J. and Peterson, J.: Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res., 64: 7491-7499 (2004).
23. Jonker, J. W., Buitelaar, M., Wagenaar, F., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plosch, T., Kuipers, F., Oude Elferink, R. P. J., Rosing, H., Beijnen, J. H. and Schinkel, A. H.: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA, 99: 15649-15654 (2002).
24. Hazlehurst, L. A., Foley, N. E., Gleason-Guzman, M. C., Hacker, M. P., Cress, A. E., Greenberger, L. W., de Jong, M. C. and Dalton, W. S.: Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res., 59: 1021-1028 (1999).
25. Rabindran, S. K., He, H., Singh, M., Brown, E., Collins, K. I., Annable, T. and Greenberger, L. M.: Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res., 58: 5850-5858 (1998).
26. Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. C. and Doyle, L. A.: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantroneselected cell lines, J. Natl. Cancer Inst., 91: 429-433 (1999).
27. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T. and Bates, S. E.: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 59: 5938-5946 (1999).
28. Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H. and Bates, S. E.: The multidrugresistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci., 113: 2011-2021 (2001).
29. Nakagawa, R., Hara, Y., Arakawa, H., Nishimura, S. and Komatani, H.: ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. Biochem. Biophys. Res. Commun., 299: 669-675 (2002).
30. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C. A. M., Ruevekamp-Helmers, M. C., Floot, B. G. J. and Schellens, J. H. M.: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 59: 4559-4563 (1999).
31. Kawabata, S., Oka, M., Shiozaw, K., Tsukamoto, K., Nakatomi, K., Sada, H., Fukuda, M., Tsurutani, J., Ikegami, Y., Sugahara, K., Yamada, Y., Kamihira, S., Doyle, L. A. Ross, D. D. and Kohno, S.: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun., 280: 1216-1223 (2001).
32. Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., Tanabe, S. and Kohno, S.: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 288: 827-832 (2001)
33. Yoshikawa, M., Ikegami, Y., Sano, K., Yoshida, H., Mitomo, H., Sawada, S. and Ishikawa, T.: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J. Exp. Ther. Oncol., 4: 25-35 (2004).
34. Ishikawa, T., Sakurai, A., Kanamori, Y., Nagakura, M., Hirano, H., Takarada, Y., Yamada, K., Fukushima, K. and Kitajima, M.: High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol., 400: 485-510, (2005).
35. Saito, H., Hirano, H., Nakagawa, H., Fukami, T., Oosumi, K., Murakami, K., Kimura, H., Kouchi, T., Konomi, M., Tao, E., Tsujikawa, N., Tarui, S., agakura, M., Osumi, M. and Ishikawa, T.: A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATPbinding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther., 317: 1114-1124 (2006).
36. Brehmer, D., Greff, Z., Godl, K., Blencke, S., Kurtenbach, A., Weber, M., Muller, S., Klebl, B., Cotton, M., Keri, G., Wissing, J. and Daub, H.: Cellular targets of gefitinib. Cancer Res., 65: 379-382 (2005).
37. Ozvegy-Laczka, C., Cserepes, J., Elkind, N. B. and Sarkadi, B.: Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat., 8: 15-26 (2005).
38. J Danceyand, J. and Sausville, E. A.: Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov., 2: 296-313 (2003).
39. Noble, M. E., Endicott, J. A. and Johnson, L. N.: Protein kinase inhibitors: insights into drug design from structure. Science, 303: 1800-1805 (2004).
40. Nurse, P. N.: Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci. Rep., 22: 487-499 (2002).
41. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R. and Roberts, J. M.: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225 (1997).
42. Tsihlias, J., Kapusta, L. and Slingerland, J.: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med., 50: 401-423 (1999).
43. An, R., Hagiya, Y., Tamura, A., Li, S., Saito, H., Tokushima, D. and Ishikawa, T.: Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res., 26: 449-458 (2009).
44. Nicolle, E., Boumendjel, A., Macalou S, Genoux, E., Ahmed-Belkacem, A., Carrupt, P. A. and Di Pietro, A.: QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv. Drug Deliv. Rev., 61: 34-46 (2008).
45. Nicolle, E., Boccard, J., Guilet, D., Dijoux-Franca, M. G., Zelefac, F., Macalou, S., Grosselin, J., Schmidt, J., Carrupt, P. A., Di Pietro, A. and Boumendjel, A.: Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur. J. Pharm. Sci., 38: 39-46 (2009).
46. Pick, A., Muller, H. and Wiese, M.: Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg. Medicin. Chem., 16: 8224-8236 (2008).
47. Tamura, A., Onishi, Y., An, R., Koshiba, S., Wakabayashi, K., Hoshijima, K., Priebe, W., Yoshida, T., Kometani, S., Matsubara, T., Mikuriya, K. and Ishikawa, T.: In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab. Pharmacokin., 22: 428-440 (2007).
48. Rousselot, P., Larghero, J., Raffoux, E., Calvo, F., Tulliez, M., Giraudier, S. and Rybojad, M.: Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br. J. Haematol, 120: 1091-1092 (2003).
49. Brazzelli, V., Prestinari, F., Barbagallo, T., Rona, C., Orlandi, E., Passamonti, F., Locatelli, F., Zecca, M., Villani, S. and Borroni, G.: A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J. Eur. Acad. Dermatol. Venereol., 21: 384-387 (2007).